


# World Journal of *Orthopedics*

World J Orthop 2011 October 18; 2(10): 93-101





## Editorial Board

2010-2014

The *World Journal of Orthopedics* Editorial Board consists of 245 members, representing a team of worldwide experts in orthopedics. They are from 30 countries, including Argentina (1), Australia (14), Austria (2), Belgium (1), Brazil (3), Canada (5), China (18), Croatia (2), Denmark (1), Egypt (2), Finland (2), France (2), Germany (10), Greece (5), Hungary (1), India (9), Iran (2), Ireland (1), Israel (5), Italy (19), Japan (14), Morocco (1), Netherlands (10), Norway (2), Portugal (1), Serbia (3), Singapore (3), South Korea (12), Spain (4), Sri Lanka (1), Sweden (3), Switzerland (6), Tunisia (3), Turkey (1), Tunisia (1), United Kingdom (6), and United States (69).

### **PRESIDENT AND EDITOR-IN-CHIEF**

Lian-Sheng Ma, *Beijing*

### **STRATEGY ASSOCIATE EDITORS-IN-CHIEF**

Jenni M Buckley, *San Francisco*  
Vijay K Goel, *Toledo*  
James F Griffith, *Hong Kong*  
Thomas W Kaminski, *Newark*  
Enrico Pola, *Rome*  
Masato Takao, *Tokyo*

### **GUEST EDITORIAL BOARD MEMBERS**

Chih-Hwa Chen, *Keelung*  
Ruei-Ming Chen, *Taipei*  
Yen-Jen Chen, *Taichung*  
Jiu-Jenq Lin, *Taiwan*  
Ko-Hsiu Lu, *Taichung*  
Chen Yuk-Kwan, *Kaohsiung*  
Fu-Chan Wei, *Taiwan*  
Ta-Sen Wei, *Taiwan*

### **MEMBERS OF THE EDITORIAL BOARD**



#### **Argentina**

Martin Alejandro Buttaró, *Aires*



#### **Australia**

Gerald J Atkins, *Adelaide*  
Gregory Ian Bain, *Adelaide*  
Belinda R Beck, *Queensland*

Adam Leigh Bryant, *Victoria*  
Darren John Beales, *Western Australia*  
Changhai Ding, *Hobart*  
Herwig Drobetz, *Mackay*  
Melanie Franklyn, *Victoria*  
Konstantin I Momot, *Queensland*  
George Samuel Murley, *Victoria*  
Michal Elisabeth Schneider-Kolsky, *Victoria*  
Gordon L Slater, *Albury*  
Mark Watsford, *Sydney*  
Cory J Xian, *Adelaide*



#### **Austria**

Florian Kutscha-Lissberg, *Vienna*  
Klemens Trieb, *Wels*



#### **Belgium**

Olivier Bruyere, *Liege*



#### **Brazil**

Francisco Bandeira Farias, *Recife*  
Djalma José Fagundes, *São Paulo*  
Eduardo Magalhães, *São Paulo*



#### **Canada**

Richard E Buckley, *Calgary*  
Reggie Charles Hamdy, *Montreal*  
Michael Anthony Hunt, *Vancouver*  
Richard Kremer, *Montreal*  
Fackson Mwale, *Montreal*



#### **China**

Yu-Ming Chen, *Guangzhou*  
Hong-Bin Fan, *Xi'an*  
Daniel YT Fong, *Hong Kong*  
Li-Xin Guo, *Shenyang*  
Xiong Guo, *Xi'an*  
Xia Guo, *Hong Kong*  
Lui-Tun Hing, *Hong Kong*  
Kai-Fu Huo, *Wuhan*  
Yong Hu, *Hong Kong*  
Xiang-Hang Luo, *Changsha*  
Marco YC Pang, *Hong Kong*  
Ming Zhang, *Hong Kong*  
Tak Chuen Wong, *Hong Kong*  
Ricky WK Wong, *Hong Kong*



#### **Croatia**

Tomislav Smoljanovic, *Zagreb*  
Robert Kolundzic, *Zagreb*



#### **Denmark**

Morten Tange Kristensen, *Copenhagen*



#### **Egypt**

Wael M.T. Koptan, *Cairo*  
Elsayed Ibraheem Elsayed Massoud, *Tahta*



#### **Finland**

Timo Järvelä, *Tampere*

Yrjö T Konttinen, *Helsinki*



### France

Federico Canavese, *Clermont-Ferrand*  
Yiou Eric, *Orsay Cedex*



### Germany

Annegret Mündermann, *Radolfzell*  
Beat Knechtle, *Gallen*  
Heinz LOHRER, *Frankfurt Am Main*  
Olaf Lorbach, *Homburg*  
Stefan Grote, *Munich*  
Karsten Knobloch, *Hannover*  
Philipp Kobbe, *Aachen*  
Volker Schöffl, *Bamberg*  
Arndt P Schulz, *Lübeck*  
Lars V Baron von Engelhardt, *Bochum*



### Greece

George C Babis, *Attiki*  
Marios Georgios Lykissas, *Ioannina*  
Lazaros I Sakkas, *Larissa*  
Nikolaos G Papadimitriou, *Thessaloniki*  
Konstantinos N Malizos, *Larissa*



### Hungary

Andor Sebestyén, *Pécs*



### India

Antony Gomes, *Calcutta*  
Kunal Sharan, *Lucknow*  
Divya Vohora, *New Delhi*  
Devdatta Suhas Neogi, *Mumbai*  
Mohamed Shafi, *Tamil Nadu State*  
Pankaj Kumar, *Andhra Pradesh*  
Pramod V Lokhande, *Pune*  
Vidyadhara Srinivasa, *Karnataka*  
Vaibhav Bagaria, *Ghaziabad*



### Iran

Hossein Negahban, *Ahvaz*  
Sayed Javad Mousavi, *Tehran*



### Ireland

Joseph S Butler, *Dublin*



### Israel

Alexander Blankstein, *Ramat Hasharon*  
Dror Lakstein, *Haifa*

Itzhak Binderman, *Tel Aviv*  
Nahum Rosenberg, *Haifa*  
Youssef Maher Masharawi, *Tel Aviv*



### Italy

Alessandro Geraci, *Feltre*  
Angelo Cacchio, *L'Aquila*  
Costantino Errani, *Bologna*  
Claudia Mazzà, *Roma*  
Donatella Lippi, *Florence*  
Giuseppe M Campo, *Messina*  
Giuseppe Banfi, *Milano*  
Patrizia D'Amelio, *Torino*  
Marco Crostelli, *Rome*  
Marcello Maggio, *Parma*  
Marco Giuseppe Angelo Teli, *Bergamo*  
Monica Mattioli-Belmonte, *Ancona*  
Marco Monticone, *Lissone*  
Pasquale De Negri, *Rionero in Vulture*  
Andrea Giusti, *Genova*  
Alberto Gobbi, *Milan*  
Raoul Saggini, *Chieti*  
Saverio Affatato, *Bologna*  
Tomaso Villa, *Milano*



### Japan

Akio Sakamoto, *Fukuoka*  
Jun Iwamoto, *Tokyo*  
Kanji Mori, *Otsu*  
Makoto Makishima, *Tokyo*  
Ryuichi Morishita, *Suita*  
Shuichi Kaneyama, *Kobe*  
Tadahiko Yotsumoto, *Osaka*  
Toru Yamaguchi, *Izumo-shi*  
Toshimasa Uemura, *Ibaraki*  
Hideki Nagashima, *Yonago*  
Hisataka Yasuda, *Nagahama*  
Yasuharu Nagano, *Saitama*  
Yoichi Aota, *Yokohama*  
Yuichi Kasai, *Tsu city*



### Morocco

Abdellah El Maghraoui, *Rabat*



### Netherlands

Claudine JC Lamothe, *Groningen*  
Barend J van Royen, *Amsterdam*  
Doug King, *Lower Hutt*  
Paul C Jutte, *Groningen*  
PE Huijsmans, *Hague*  
PM van der Kraan, *Nijmegen*  
Michel van den Bekerom, *Amsterdam*  
JJ Verlaan, *Utrecht*  
Rob GHH Nelissen, *Leiden*  
Taco Gosens, *Tilburg*



### Norway

Jan Oxholm Gordeladze, *Oslo*  
Gunnar Knutsen, *Tromsø*



### Portugal

João F Mano, *Guimarães*



### Serbia

Radica Dunjic, *Belgrade*  
Miroslav Z Milankov, *Novi Sad*  
Zoran Vukasinovic, *Belgrade*



### Singapore

Anselm Mak, *Singapore*  
Dongan Wang, *Singapore*  
V Prem Kumar, *Singapore*



### South Korea

Dae-Geun Jeon, *Seoul*  
Seok Woo Kim, *Gyeonggi*  
Sang-Hun Ko, *Ulsan*  
Sung-Uk Kuh, *Seoul*  
Jaebeom Lee, *Miryang*  
Yong Seuk Lee, *Suwon*  
Hyun Woo Kim, *Seoul*  
Jae Taek Hong, *Suwon*  
Jong-Beom Park, *Kyunggi-do*  
Kook Jin Chung, *Seoul*  
Kyu Hyun Yang, *Seoul*  
Sang Ki Lee, *Daejeon*



### Spain

Antonio Herrera, *Zaragoza*  
Daniel Hernandez Vaquero, *Aviles*  
Francisco J Blanco, *A Coruña*  
Nuria Vilaboa, *Madrid*



### Sri Lanka

Janaka Lenora, *Galle*



### Sweden

Jan G Jakobsson, *Stockholm*  
Anna Nordström, *Umeå*



### Switzerland

Achim Elfering, *Bern*  
Benjamin Gantenbein, *Bern*

Nicola A Maffioletti, *Zurich*  
Michael Hirschmann, *Basel*  
Elyazid Mouhsine, *Lausanne*  
Peter Fennema, *Baar*



#### **Thailand**

Boonsin Tangtrakulwanich, *Songkla*  
Prachya Kongtawelert, *Chiang Mai*  
Sittisak Honsawek, *Bangkok*



#### **Tunisia**

Lamia Rezgui-Marhouf, *Tunis*



#### **Turkey**

Akmer Mutlu, *Ankara*  
Bulent Daglar, *Ankara*  
Kemal NAS, *Diyarbakir*  
Salih Özgöçmen, *Kayseri*  
Serdar Kahraman, *Istanbul*



#### **United Kingdom**

Henry DE Atkinson, *London*  
Vikas Khanduja, *Cambridge*  
Ali Mobasheri, *Sutton Bonington*  
Charles Anthony Willis-Owen, *London*  
Vikki Wylde, *Bristol*  
Tosan Okoro, *Bangor*



#### **United States**

Srino Bharam, *New York*  
Craig R Bottoni, *Honolulu*  
Lavjay Butani, *Sacramento*  
Chaoyang Chen, *Detroit*  
Ock K Chun, *Storrs*  
Christopher J Colloca, *Chandler*  
Nabanita S Datta, *Detroit*  
Paul E Di Cesare, *Sacramento*  
Matthew B Dobbs, *Saint Louis*  
Evan F Fkman, *Columbia*  
Joel J Gagnier, *Ann Arbor*  
Federico P Girardi, *New York*  
David L Helfet, *New York*  
Johnny Huard, *Pittsburgh*  
Stefan Judex, *Stony Brook*  
Monroe Laborde, *New Orleans*  
Bingyun Li, *Morgantown*  
Subburaman Mohan, *Loma Linda*  
Arash Momeni, *Palo Alto*  
Nader D Nader, *Buffalo*  
John Nyland, *Louisville*  
Karin Gräware Silbernagel, *Newark*  
David H Song, *Chicago*  
Nelson F SooHoo, *Los Angeles*  
SPA Stawicki, *Columbus*  
Ann Marie Swank, *Louisville*  
R Shane Tubbs, *Birmingham*  
Victoria M Virador, *Bethesda*  
Savio LY Woo, *Pittsburgh*  
Masayoshi Yamaguchi, *Atlanta*  
Feng-Chun Yang, *Indianapolis*  
Subhashini Yaturu, *Albany*

Hiroki Yokota, *Troy*  
Charalampos Zalavras, *Los Angeles*  
Chunfeng Zhao, *Rochester*  
Anil Bhawe, *Baltimore*  
John Elias, *Akron*  
Clark Dickin, *Muncie*  
John S Early, *Dallas*  
James S Harrop, *Philadelphia*  
Adam H Hsieh, *Maryland*  
Aditya V Maheshwari, *New York*  
Zong-Ming Li, *Cleveland*  
Richard M Lovering, *Baltimore*  
Lyle Joseph Micheli, *Boston*  
Ming Pei, *Morgantown*  
Juan A Pretell – Mazzini, *Philadelphia*  
David M Selkowitz, *Pomona*  
Hassan Serhan, *Raynham*  
Subhashini Yaturu, *Albany*  
Sorin Siegler, *Pennsylvania*  
Aaron David Sciascia, *Lexington*  
Jeffrey C Wang, *Santa Monica*  
David Andrew Spiegel, *Philadelphia*  
Inna Belfer, *Pittsburgh*  
Angie Botto-van Bemden, *Lauderdale*  
Quan-Jun Cui, *Virginia*  
Scott D Daffner, *Morgantown*  
B Sonny Bal, *Columbia*  
Beril Gok, *Baltimore*  
Ashraf S Gorgey, *Richmond*  
Kee D Kim, *Sacramento*  
Brian Michael Haus, *Boston*  
Dror Paley, *Pittsburgh*  
Bing Wang, *Pittsburgh*  
Wen-Bao Wang, *New York*  
Li-Qun Zhang, *Chicago*  
Nigel Zheng, *Charlotte*

**REVIEW**

- 93      Role of polyethylene particles in peri-prosthetic osteolysis: A review

*Atkins GJ, Haynes DR, Howie DW, Findlay DM*

## Contents

*World Journal of Orthopedics*  
Volume 2 Number 10 October 18, 2011

**ACKNOWLEDGMENTS** I Acknowledgments to reviewers of *World Journal of Orthopedics*

**APPENDIX** I Meetings  
I-V Instructions to authors

**ABOUT COVER** Atkins GJ, Haynes DR, Howie DW, Findlay DM. Role of polyethylene particles in peri-prosthetic osteolysis: A review.  
*World J Orthop* 2011; 2(10): 93-101  
<http://www.wjgnet.com/2218-5836/full/v2/i10/93.htm>

**AIM AND SCOPE** *World Journal of Orthopedics* (*World J Orthop*, *WJO*, online ISSN 2218-5836, DOI: 10.5312) is a monthly peer-reviewed, online, open-access, journal supported by an editorial board consisting of 245 experts in orthopedics from 30 countries.  
The aim of *WJO* is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of orthopedics. *WJO* covers diagnostic imaging, arthroscopy, evidence-based medicine, epidemiology, nursing, sports medicine, therapy of bone and spinal diseases, bone trauma, osteoarthritis, bone tumors and osteoporosis, minimally invasive therapy, traditional medicine, and integrated Chinese and Western medicine. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to orthopedics, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

**FLYLEAF** I-II Editorial Board

## EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiao-Cui Yang*  
Responsible Electronic Editor: *Xiao-Cui Yang*  
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Xing Wu*  
Proofing Editorial Office Director: *Xiao-Cui Yang*

**NAME OF JOURNAL**  
*World Journal of Orthopedics*

**LAUNCH DATE**  
November 18, 2010

**SPONSOR**  
Beijing Baishideng BioMed Scientific Co., Ltd.  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-8538-1892  
Fax: +86-10-8538-1893  
E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**EDITING**  
Editorial Board of *World Journal of Orthopedics*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-5908-0036  
Fax: +86-10-8538-1893  
E-mail: [wjo@wjgnet.com](mailto:wjo@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLISHING**  
Baishideng Publishing Group Co., Limited  
Room 1701, 17/F, Henan Building,  
No.90 Jaffe Road, Wanchai, Hong Kong, China  
Fax: +852-3115-8812

Telephone: +852-5804-2046  
E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**SUBSCRIPTION**  
Beijing Baishideng BioMed Scientific Co., Ltd.  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-8538-1892  
Fax: +86-10-8538-1893  
E-mail: [baishideng@wjgnet.com](mailto:baishideng@wjgnet.com)  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
October 18, 2011

**ISSN**  
ISSN 2218-5836 (online)

**PRESIDENT AND EDITOR-IN-CHIEF**  
*Lian-Sheng Ma, Beijing*

**STRATEGY ASSOCIATE EDITORS-IN-CHIEF**  
*Enrico Pola, Rome*  
*Masato Takao, Tokyo*  
*James F Griffith, Hong Kong*  
*Thomas W Kaminski, Newark*  
*Jenni M Buckley, San Francisco*  
*Vijay K Goel, Toledo*

**EDITORIAL OFFICE**  
*Xiao-Cui Yang, Assistant Director*  
*World Journal of Orthopedics*  
Room 903, Building D, Ocean International Center,  
No. 62 Dongsihuan Zhonglu, Chaoyang District,  
Beijing 100025, China  
Telephone: +86-10-8538-1892  
Fax: +86-10-8538-1893  
E-mail: [wjo@wjgnet.com](mailto:wjo@wjgnet.com)  
<http://www.wjgnet.com>

**COPYRIGHT**  
© 2011 Baishideng. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**  
All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

**INSTRUCTIONS TO AUTHORS**  
Full instructions are available online at [http://www.wjgnet.com/2218-5836/g\\_info\\_20100722172650.htm](http://www.wjgnet.com/2218-5836/g_info_20100722172650.htm).

**ONLINE SUBMISSION**  
<http://www.wjgnet.com/2218-5836office>



## Role of polyethylene particles in peri-prosthetic osteolysis: A review

Gerald J Atkins, David R Haynes, Donald W Howie, David M Findlay

Gerald J Atkins, Donald W Howie, David M Findlay, Discipline of Orthopaedics and Trauma, The University of Adelaide, South Australia 5005, Australia

David R Haynes, Discipline of Pathology, The University of Adelaide, South Australia 5005, Australia

**Author contributions:** Atkins GJ and Findlay DM drafted the manuscript; all authors contributed to the conceptual design and editing; Atkins GJ designed the figure.

Supported by National Health and Medical Research Council of Australia

Correspondence to: Gerald J Atkins, Associate Professor, Discipline of Orthopaedics and Trauma, The University of Adelaide, South Australia 5005, Australia. [gerald.atkins@adelaide.edu.au](mailto:gerald.atkins@adelaide.edu.au)

Telephone: +61-8-82223054 Fax: +61-8-82323065

Received: September 1, 2011 Revised: September 30, 2011

Accepted: October 7, 2011

Published online: October 18, 2011

containing newer, highly cross-linked PEs (HXLPEs), for which osteolysis seems to occur with much reduced PE wear compared with conventional PEs. The caveat here is that we know little as yet about the bioactivity of HXLPE particles and addressing this constitutes our next challenge.

© 2011 Baishideng. All rights reserved.

**Key words:** Polyethylene; Aseptic loosening; Osteolysis; Wear particle; Peri-prosthetic

**Peer reviewers:** Antonio Herrera, Professor, Orthopaedic Surgery and Traumatology Miguel Servet University Hospital, Avenue Isabel la Católica 1, Zaragoza 50009, Spain; Nuria Vilaboa, Dr., Hospital Universitario La-Paz-IdiPAZ Edificio de I+D Paseo de La Castellana 261, 28046 Madrid, Spain; Konstantin I Momot, PhD, Queensland University of Technology, GPO Box 2434, Brisbane, Qld 4001, Australia

### Abstract

There is convincing evidence that particles produced by the wear of joint prostheses are causal in the peri-prosthetic loss of bone, or osteolysis, which, if it progresses, leads to the phenomenon of aseptic loosening. It is important to fully understand the biology of this bone loss because it threatens prosthesis survival, and loosened implants can result in peri-prosthetic fracture, which is disastrous for the patient and presents a difficult surgical scenario. The focus of this review is the bioactivity of polyethylene (PE) particles, since there is evidence that these are major players in the development and progression of osteolysis around prostheses which use PE as the bearing surface. The review describes the biological consequences of interaction of PE particles with macrophages, osteoclasts and cells of the osteoblast lineage, including osteocytes. It explores the possible cellular mechanisms of action of PE and seeks to use the findings to date to propose potential non-surgical treatments for osteolysis. In particular, a non-surgical approach is likely to be applicable to implants

Atkins GJ, Haynes DR, Howie DW, Findlay DM. Role of polyethylene particles in peri-prosthetic osteolysis: A review. *World J Orthop* 2011; 2(10): 93-101 Available from: URL: <http://www.wjgnet.com/2218-5836/full/v2/i10/93.htm> DOI: <http://dx.doi.org/10.5312/wjo.v2.i10.93>

### INTRODUCTION

Total hip replacement (THR), although a highly successful procedure, can fail prematurely for a number of reasons. The most common cause of failure of THR in the mid- to long-term is aseptic loosening associated with peri-implant bone loss (termed osteolysis)<sup>[1,2]</sup>. Revision THR is considerably more difficult than primary THR and carries a higher rate of morbidity and mortality. The loss of bone stock jeopardises surgery to revise the prosthesis and reconstruct the joint. Furthermore, when osteolysis has weakened the bone to the extent that peri-prosthetic fracture occurs, the result is not only devastating to the affected individual but is also extremely chal-

lenging surgically, with poor long-term success rates in rebuilding the fractured bone, especially in the pelvis. Unless implants can be made to last longer in patients, the numbers of revision surgeries will continue to increase because of population aging, increasing life expectancies and a growing expectation of joint replacement surgery by young, active individuals with arthritic joints.

## POLYETHYLENE WEAR PARTICLES AS A CAUSE OF PERI-PROSTHETIC OSTEOLYSIS

The concept that particulates released from prosthetic components by wear of the articular surfaces are important causative agents in peri-prosthetic osteolysis is well accepted<sup>[3]</sup>, although other factors are also likely to be important, including access of particles to bone sites and hydrostatic pressure<sup>[4,5]</sup>. Most commonly, hip prostheses have metal or ceramic on polyethylene (PE) articulations. It is now well established that PE, metal<sup>[6]</sup>, alumina<sup>[7]</sup> and polymethylmethacrylate (PMMA) particles<sup>[8]</sup> all have bioactivity and could therefore be involved in the events leading to osteolysis. Evidence suggests that PE wear particles may be most important in peri-prosthetic bone loss around articulations with PE linings<sup>[9-11]</sup>. Our own results show that wear of PE bearing surfaces correlates strongly with the extent of osteolysis, and that patients with a high volumetric wear rate exhibited the greatest progression of lesion volume<sup>[12]</sup>. This review will therefore focus on PE as a key agent of bone loss in osteolysis and on the bioactivity of particulates of this material. In addition, the review will deal exclusively with THR. Wear-related osteolysis also occurs adjacent to total knee replacements in the medium to long-term (reviewed by Gupta *et al.*<sup>[13]</sup>) but the features of this are sufficiently distinct as to require separate consideration.

## EFFECT OF SIZE, MORPHOLOGY AND CHEMICAL FORM OF PE PARTICLES


Most of the investigative studies into PE particles to date are of conventional ultra high molecular weight PE (UHMWPE), with some more recent studies of PE that has been cross-linked by various methodologies. It is clear that the size of PE particles is a factor in cell responses *in vivo*<sup>[14]</sup> and *in vitro*. A comparison by Matthews *et al.*<sup>[15]</sup> showed that human monocyte-like cells were most responsive to particles in the size range 0.21-7.2  $\mu\text{m}$ , depending on the readout, with larger particles of 88  $\mu\text{m}$  evoking little response. The morphology of particles also appears to contribute to cellular responses, with UHMWPE debris with a roughened surface and a fibular shape provoking a greater response in terms of inflammatory cytokine production in a murine inflammation model than particles with a smooth surface and a globular shape<sup>[16]</sup>. The clinical evidence cited above showing strong relationships between PE wear and osteolysis

is for implants that contain conventional UHMWPE. In order to reduce wear and as a consequence also reduce osteolysis, highly cross-linked PEs (HXLPE) have been developed (reviewed in<sup>[17]</sup>), which are now used almost universally in hip replacements. Although measurable wear still occurs, HXLPE components do show greatly reduced rates of wear, both in hip simulators and in clinical use<sup>[18,19]</sup>. However, while the use of HXLPE has reduced the early incidence of osteolysis compared with conventional PE<sup>[20]</sup>, it has not eliminated the problem, with osteolysis still being observed 5-7 years after THR with prostheses containing HXLPE bearings<sup>[21-24]</sup>. It will therefore be important to understand the bioactivity of HXLPE particles in comparison with conventional PE particles, since there is a paucity of data so far. Endo *et al.*<sup>[25]</sup> found that higher percentages of small wear particles, namely those in the 0.1-1  $\mu\text{m}$  range, were produced during laboratory wear of cross-linked PE than conventional PE. These authors also found that smaller numbers of HXLPE particles than for conventional PE were required to stimulate cytokine production from macrophages, possibly because of the higher percentage of smaller particles of HXLPE and the increased ability of cells to phagocytose smaller particles<sup>[15]</sup>. HXLPE particles may interact with cells differently, since Ilgen *et al.*<sup>[26]</sup> showed that crosslinked PE particles had altered bioactivity, which was unrelated to particle size. Particles of PE were crosslinked by electron-beam irradiation in nitrogen at 10 and 40 MRad to produce particles of the same size but with different extents of crosslinking. The crosslinked particles produced more inflammation and osteolysis (35%) in a murine calvarial osteolysis model than did control non-crosslinked particles (9%). Finally, endotoxin adherent to wear particles is also involved in the biological responses to these particles<sup>[27]</sup>. Taken together, these data strongly suggest that the bioactivity of PE particles depends on the size and material properties of the PE.

## PE PARTICLES IN PERIPROSTHETIC TISSUES

Bone that is removed by the osteolytic process is replaced by a granulomatous connective tissue consisting of numerous cell types, including monocytes, macrophages, lymphocytes, endothelial cells and fibrohistiocytic infiltration in association with particulate debris<sup>[28-32]</sup>. Jacobs *et al.*<sup>[30]</sup> have also made the point that these cells are often in close association with osteoblasts and osteoclasts so that elucidating the biology of periprosthetic bone loss requires taking into account the coordinated actions of all these cell types. Takagi *et al.*<sup>[29]</sup> administered fluorescent label to patients prior to revision surgery for loose hip prostheses and found by histological analysis that sites of osteolysis were characterized by a unique high turnover bone remodeling. They reported evidence of osteoclastic resorption accompanied by increased mineral apposition rate and bone formation rate, producing apparently im-





**Figure 1** Multi-cellular effects of polyethylene wear particles, following their release from the bearing surface, resulting in osteolysis. Polyethylene (PE) engulfment by monocytes and macrophages, and possibly other cells including fibroblasts, as described in the text, causes their activation and release of pro-inflammatory cytokines, prostaglandins and matrix degrading enzymes. These and other factors promote differentiation of macrophages into bone resorbing osteoclasts. PE effects on osteoblastic lineage cells (osteoblasts, lining cells and potentially osteocytes) following contact with and/or engulfment of particles include promotion of a catabolic phenotype, up-regulation of potent chemotactic agents for osteoclast precursors and osteoclastogenic mediators. The responses in each cell type are indicated by boxed arrows. RANKL:receptor activator of nuclear factor- $\kappa$ B ligand; OPG: osteoprotegerin; M-CSF: macrophage colony stimulating factor; MMPs: Matrix metalloproteinases.

mature bone matrices with poor bone quality, containing abundant osteocytes. In the granulomatous tissues adjacent to PE containing prostheses, PE particulates are found in large numbers, usually engulfed by cells with a macrophage appearance<sup>[33,34]</sup>. Kobayashi *et al.*<sup>[35]</sup> analysed peri-implant tissue from patients having revision knee replacement surgery and concluded that PE particles were most concentrated at sites of osteolysis. We and others have probed the molecular milieu of the tissue at sites of osteolysis and the factors identified combine to present a distinct catabolic profile. Matrix metalloproteinases (MMP), including MMPs-1, 2, 3, 9 and MT1-MMP, are abundant in this tissue and show an imbalance with their respective endogenous inhibitors<sup>[36,37]</sup>. The interface tissues around failed prostheses have also been found to be acidic and to contain high levels of the collagenase cathepsin K<sup>[38]</sup>. Production of these matrix degrading enzymes is likely secondary to the large number of cytokines, many proinflammatory, which have been identified in these tissues. These include interleukin (IL)-1 $\alpha$  and  $\beta$ , IL-2, IL-6, IL-11, macrophage colony stimulating factor (M-CSF), monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1 $\alpha$ , transforming growth factor  $\beta$ , tumor necrosis factor (TNF)- $\alpha$ , granulocyte macrophage (GM)-CSF, platelet derived growth factor and interferon  $\gamma$ <sup>[31,39-43]</sup>. In addition to these factors, we have shown that an accumulation of PE particles is also frequently associated with a marked increase in receptor activator of nuclear factor- $\kappa$ B (RANK) and RANK ligand (RANKL) expression<sup>[34,40]</sup>. It is now established that the activated RANKL/RANK ligand-receptor complex promotes physiological osteoclast differentiation

and activity<sup>[44]</sup>. The expression and activity of RANKL is known to be induced by a number of proinflammatory cytokines factors and there is evidence<sup>[40,45]</sup> that TNF- $\alpha$  can greatly enhance RANKL activity. The implication of this is that RANKL expression, induced in cells in the inflammatory tissue in response to prosthetic wear particles, could promote the influx of osteoclast precursors and drive osteoclastic differentiation and activity, thus promoting osteolysis. In support of this, RANKL inhibitors appear to be a promising treatment modality for particle-induced osteolysis (see below). Confirmation that the pathological changes seen in tissues adjacent to osteolysis, and osteolysis itself, are caused by PE particles, has been obtained by the demonstration in animal models that infusion of PE particles recapitulates many of the phenomena described above. For example, intramedullary infusion of PE particles in murine models resulted in reduced bone volume<sup>[46]</sup> and formation of proliferative fibrous tissue with increased expression of IL-1, IL-6 and TNF- $\alpha$ <sup>[11]</sup>.

## PE PARTICLES AND MACROPHAGES

As reviewed previously<sup>[47]</sup>, the prevailing view of the cellular mechanism of particle-induced osteolysis is that macrophages in the periprosthetic tissues phagocytose wear particles and become activated, releasing an array of cytokines, leading to increased osteoclastic resorption of the adjacent bone and the production of the granulomatous tissue that fills the resorbed space (Figure 1). Experiments performed to better understand the interaction between PE particles and monocyte/macrophages are challenging because of the extreme hydrophobicity

of PE particles, reflected by the relatively small number of reports. However, Ren *et al.*<sup>[48]</sup> performed elegant experiments to investigate whether responses to PE particles were by resident or infiltrating macrophages. In a mouse model of UHMWPE-induced osteolysis and using a bioluminescent approach to monitor systemic migrating macrophages *in vivo*, it was found that infusion of particles stimulated systemic migration of remotely injected macrophages, leading to net bone loss at the site of PE particles. Evidence that PE particles directly affect macrophages comes from a study by Horowitz *et al.*<sup>[49]</sup>, in which J774 macrophage-like cells exposed to PE particles produced increased TNF- $\alpha$ , prostaglandin (PG)E<sub>2</sub> and IL-6. In addition, it was shown that conditioned media from the macrophages exposed to PE particles increased the release of <sup>45</sup>Ca from pre-labelled mouse calvariae, which could be prevented by co-addition of pamidronate bisphosphonate. An important role for macrophages is also inferred from a study by Ren *et al.*<sup>[50]</sup>, in which depletion of macrophages using clodronate significantly reduced inflammation in a mouse air pouch model of UHMWPE-induced tissue inflammation. Together, these experiments provide proof of principle that macrophages exposed to PE particles release mediators that can stimulate bone resorption. Finally, we<sup>[51,52]</sup> and others<sup>[53]</sup> have shown that macrophages isolated from peri-prosthetic tissues that have phagocytosed wear particles, are themselves capable of differentiating into bone resorbing osteoclasts.

## PE PARTICLES AND OSTEOCLASTS

Although it is possible that wear particle-activated macrophages present in granulomatous tissue participate directly in bone degradation in periprosthetic osteolysis, bone resorption is more likely a function of osteoclasts recruited to sites of osteolysis and activated by the osteoclastogenic molecules that are expressed in abundance at such sites. These molecules, listed above, comprise chemoattractants that result in the influx of osteoclast precursors, thought to be cells of the monocyte lineage, and cytokines that stimulate osteoclast differentiation. It is generally acknowledged that the major pathway of osteoclastogenesis is the production of RANKL by osteoblastic stromal cells<sup>[54,55]</sup> and ligation of RANKL to its cognate receptor, RANK, on the surface of osteoclast precursors, stimulating these cells to differentiate into mature, active osteoclasts capable of resorbing bone. The natural antagonist of RANKL is osteoprotegerin (OPG), whose role is to negatively regulate the activity of RANKL, and therefore bone resorption. Other cell types, including fibroblasts<sup>[56,57]</sup>, osteocytes<sup>[58]</sup> and activated T cells<sup>[59]</sup>, also produce RANKL and are capable of stimulating osteoclastogenesis. We have shown that the RANKL pathway is subverted in a range of pathologies characterised by bone loss, including peri-implant osteolysis<sup>[34,60-62]</sup>. Studies on healthy and pathologic synovial tissues show that a number of cell types may be important in the ectopic production of RANKL in the tissues adjacent to localized bone loss. Importantly, there is evi-

dence for a reduction of the OPG:RANKL ratio in PE-induced osteolysis, seen for example in experiments in which mouse calvariae were implanted with PE particles, associated with reduction of bone volume<sup>[63]</sup> and in peri-prosthetic human tissues<sup>[31]</sup>.

Various cytokines collaborate with RANKL to promote osteoclast formation, in particular M-CSF, which is an essential co-activator of osteoclastogenesis from immature precursors<sup>[54,64]</sup>. However, we recently showed that RANKL and M-CSF alone were not sufficient for osteoclast differentiation of osteoclasts from a murine macrophage cell line RAW 264.7 and that other cytokines and steroidal hormones were essential in this process. Indeed, in a defined culture medium in the absence of serum, osteoclast formation from primary cells, such as human peripheral blood mononuclear cells, did not occur at all, despite the presence of high concentrations of RANKL, M-CSF and other co-factors<sup>[65]</sup>, underscoring the likely significant contributions of the complex milieu present in peri-prosthetic granulomatous tissue.

TNF- $\alpha$  is also present in the tissues adjacent to peri-prosthetic osteolysis and has been reported to synergise with RANKL in promoting osteoclast formation<sup>[45]</sup>. It has also been claimed that, in the presence of M-CSF, TNF- $\alpha$  is sufficient for inducing human osteoclast differentiation from arthroplasty macrophages<sup>[53]</sup>. By immunohistochemical analysis of tissues associated with osteolysis obtained at revision surgery, RANK, RANKL and TNF- $\alpha$  were all found to be strongly expressed by large multinucleated cells containing PE wear debris<sup>[40]</sup>. Control synovial tissue stained weakly for these cytokines. A strong statistical correlation was found between the parameters of: volume of bone lost (determined by quantitative computed tomography;  $r = 0.65$ ,  $P = 0.01$ ); PE wear debris (number of particles;  $r = 0.67$ ,  $P < 0.01$ ), RANK ( $r = 0.67$ ,  $P < 0.01$ ), RANKL ( $r = 0.81$ ,  $P < 0.01$ ) and TNF- $\alpha$  ( $r = 0.65$ ,  $P = 0.01$ ) expression. In the same study, it was shown that RANKL and TNF- $\alpha$  synergise to increase the volume of bone resorbed. These data suggested that the interaction of TNF- $\alpha$  and RANKL may promote osteoclast activity associated with PE particles and perhaps that therapies targeting TNF activity may be useful to treat peri-implant osteolysis.

Chemokines are involved in the recruitment of many types of cells but it is those that are involved in the recruitment of monocytes/macrophages and lymphocytes that are likely to be most important in peri-prosthetic osteolysis. Chemokines present in periprosthetic tissues include MCP-1, MIP-1 $\alpha$ , RANTES and IL-8, whose release is stimulated by wear particles and which are chemotactic for monocytic osteoclast precursors<sup>[66]</sup>. Finally, RANKL expression itself is stimulated by many of the pro-inflammatory cytokines that are found in the peri-implant tissues. The above effects of PE particles are summarised in Figure 1.

## PE PARTICLES AND CELLS OF THE OSTEOBLAST LINEAGE

PE particles can interact with cells of the osteoblast

lineage indirectly *via* products released by PE activated macrophages<sup>[67]</sup>. There is also evidence of direct effects of PE particles on osteoblasts. Exposure of osteoblast-like cells to PE was shown to induce changes in the rate of cell proliferation<sup>[68-70]</sup>, to decrease alkaline phosphatase activity<sup>[69]</sup>, and to increase the production of osteoclastogenic mediators, such as PGE<sub>2</sub><sup>[69]</sup>, IL-6<sup>[71,72]</sup>, GM-CSF, RANKL<sup>[73]</sup> and nitric oxide<sup>[74]</sup>. The nature of the response may be dependent on the way in which the PE particles are presented to the cells and to the maturation state of the osteoblasts<sup>[74]</sup>. However, the overall effect of PE particles on osteoblasts is one of promoting a phenotype that is anti-anabolic and pro-osteoclastic. For example, UHMWPE particles increased the release of RANKL from human osteoblasts, while inhibiting their expression of OPG. Consistent with this, conditioned media from the PE-treated osteoblasts strongly promoted osteoclastogenesis from human peripheral blood mononuclear cells<sup>[73]</sup>. Given the extreme hydrophobicity of the particles, we developed a 3-dimensional type I collagen gel culture system, allowing long-term culture of osteoblastic cells in the continued juxtaposition of PE particles in a bone connective tissue-like matrix. This system allowed human bone-derived osteoblasts obtained at joint replacement surgery to undergo differentiation into a mature osteocyte-like phenotype over a 21-28 day culture period<sup>[58,75]</sup>. Following release of the cells from the gel, it was evident that PE particles could form close contacts with these cells and in some cases appeared to be engulfed<sup>[58]</sup>. Importantly, cells exposed to PE particles showed an increase in mRNA expression of the late osteoblast/osteocyte markers E11, dentin matrix protein 1 and the gene encoding sclerostin (SOST) and increased expression of several of the genes discussed above to be associated with osteoclast formation and activity (RANKL, M-CSF and IL-8), with a concomitant decrease in the expression of OPG<sup>[58]</sup>. Furthermore, it appeared that under the influence of PE, the key transcription factor RUNX2 in these cells switched from controlling matrix production genes (type I collagen) to inducing the expression of genes associated with osteoclast recruitment, differentiation and activation. This study provided further evidence that PE particles switch mature osteoblastic cells from an anabolic to a catabolic phenotype, a concept further supported by the finding that PE particles induced expression of RANKL mRNA in the mouse osteocyte cell line, MLO-Y4. Overall, our results suggest that PE particles act directly on cells of the osteoblast lineage to induce a change in the phenotype of mature osteoblasts and osteocytes<sup>[58]</sup>, consistent with the net loss of bone near orthopedic implants.

## INVOLVEMENT OF THE INNATE IMMUNE RESPONSE IN THE RESPONSE TO PE PARTICLES

Little is known about the way in which PE particles interact with cells or how this interaction is transduced into

intracellular signals. It appears that particles need to be phagocytosed to elicit a signal in macrophages and osteoclasts, and possibly also osteoblasts and osteocytes, as discussed above. It is possible that cells first interact with PE particles *via* proteins adsorbed to the particle surface, rather than with the PE material itself, either with endotoxin<sup>[27]</sup> or other proteins<sup>[76]</sup>. There is evidence that activation of Toll-like receptors (TLRs) may contribute to the biological activity of the wear particles. Maitra *et al*<sup>[77]</sup>, in a study which explored the cellular mechanisms of interaction of UHMWPE with peripheral blood monocytes, found that polymeric alkane UHMWPE breakdown products with side chain oxidation directly bound and activated the TLR1/2 signalling pathway. They showed that phagocytosis of particulates in the larger micron- and nanometer sized range induced enlargement, fusion and disruption of endosomal compartments, resulting in lysosomal damage and enzymatic leakage with release of cathepsins S and B, as well as caspase 1 activation and processing of pro-IL-1 and pro-IL-18. The authors reported that the two processes of TLR activation and phagocytosis synergistically initiated a strong inflammatory response associated with cell death and extracellular matrix degradation. Hao *et al*<sup>[78]</sup> reported that heat-shock protein (Hsp) expression was elevated when monocytes were exposed to UHMWPE particles. They showed that TLR4 was involved in the recognition of particles and subsequent induction of intracellular signalling cascades and that anti-sense oligonucleotide down-regulation of TLR4 expression suppressed cytokine production in both exogenous Hsp60- and particle-stimulated cultures. Adherent endotoxin was found to be important in the activation of monocytes with titanium particles<sup>[27]</sup>. Mice that were 'endotoxin resistant' due to a mutation in TLR4 were less responsive to endotoxin coated titanium particles than cells from wild-type mice were. Taken together, the extant studies point to the innate immune response as being responsible for at least some of the cellular responses to PE and other wear particles, with a possible role for both adherent endotoxin (and other proteins) interacting with TLRs.

## NON-SURGICAL TREATMENT OF OSTEOLYSIS

With conventional PE, large volumetric osteolysis is almost always accompanied by considerable wear of the PE liner, and in this case liner replacement at revision surgery is indicated. In the case of implants with HXLPE liners, acetabular osteolysis occurs with relatively little obvious wear due to the wear resistant nature of this material. Thus, while there may currently be limited opportunities to treat osteolysis from conventional PE non-surgically, such an approach may be feasible with HXLPE, the caveat being that we know very little to date about the bioactivity of HXLPE particles.

Bisphosphonates are a class of drug with the dual features of potent anti-resorptive efficacy and high up-



take in the skeleton. While most commonly prescribed for the treatment of osteoporosis, Paget's disease and for certain types of cancer, wider applicability including the treatment of peri-prosthetic osteolysis has also been proposed<sup>[79]</sup>. Indeed, several bisphosphonates show promise as therapeutic agents for particle-induced bone loss. Alendronate has proved efficacious in both rat<sup>[80]</sup> and dog<sup>[81]</sup> models of PE-induced periprosthetic osteolysis. Similarly, the bisphosphonate TRK-530 suppressed bone loss in a rat model of continuous infusion of PE particles into the bone and reduced the expression of inflammatory mediators<sup>[82]</sup>. Pamidronate was able to prevent resorption of explanted calvariae exposed to conditioned medium from PE-treated macrophages<sup>[49]</sup>. In a clinical case study, O'Hara *et al.*<sup>[83]</sup> reported that oral alendronate halted the progression of osteolysis over the course of 1 year prior to revision surgery to replace the PE liner. By virtue of what is currently understood regarding the general mechanism of action of bisphosphonates, these data suggest that osteoclasts represent a valuable potential target to prevent or treat osteolysis. Thus, other treatment strategies that target osteoclasts may also be applicable. For example, it is possible that anti-RANKL strategies could be effective in blocking osteolysis. In support of this, OPG has been shown to suppress both UHMWPE<sup>[84]</sup> and titanium<sup>[85]</sup> particle induced osteolysis in the mouse calvarial model. Interestingly, RANK:Fc, an alternative approach to blocking RANKL action, was also effective in the calvarial model, where it also allowed restoration of bone lost by osteolysis<sup>[86]</sup>. Another therapeutic approach to osteolysis may be to treat the underlying inflammation, which creates a catabolic environment, including the production of RANKL and MMPs. Approaches to this that have been experimentally successful include local treatment with the inflammatory suppressor, IL-10, which prevented a fibrotic reaction and allowed bone growth in the presence of PE particles<sup>[87]</sup>. Also, anti-TNF- $\alpha$  gene therapy was able to inhibit a resorptive response to titanium particles in the mouse calvarial model<sup>[88]</sup>, although administration of the TNF antagonist etanercept to patients with peri-prosthetic osteolysis produced equivocal results, perhaps because the study was underpowered<sup>[89]</sup>. Such a targeted approach in human patients may be ineffectual, or at least not generally applicable, because of the multi-factorial nature of the inflammatory response to particles, as discussed above. MMP inhibitors have also been suggested for use in the context of osteolysis<sup>[36]</sup>, given the abundance of MMPs in periprosthetic tissues. However, anti-MMP approaches have proven disappointing to date<sup>[90]</sup>, perhaps awaiting more specific agents or better methods for local application. Perhaps, as suggested by Schwarz<sup>[91]</sup>, prophylactic treatment immediately post operatively to optimise the osseointegration of the implant and therefore reduce access to the bone of wear particles, may inhibit the initiation and progression of particle-induced osteolysis.

One of the potential problems of a non-surgical approach to the treatment of osteolysis associated with

HXLPE liners may be the problem of replacing the lost bone. It is noteworthy that while some agents have been shown to promote bone formation in the context of particle induced mouse calvarial osteolysis<sup>[92,93]</sup>, it remains to be seen if these or other approaches will be effective in more refractory skeleton of the aging human adult. Of the new and emerging anabolic agents in bone, sclerostin antagonists to date appear promising, with evidence of widespread new bone growth throughout the skeleton in both healthy bone and in a number of conditions of bone loss<sup>[94]</sup>.

## CONCLUSION

This review shows that we have come a long way in understanding the bioactivity of PE particles and the mechanisms by which an accumulation of these particles elicits a characteristic tissue response leading to bone loss around PE-containing implants. This knowledge is important because it has the potential to enable non-surgical approaches to managing PE-induced osteolysis, particularly in implants containing the newer HXLPEs, for which osteolysis seems, from observations so far, to occur without substantial PE wear. The caveat here is that we currently know little about the bioactivity of HXLPE particles, and our next task needs to be to address this knowledge gap. It will also be important to address the issue of bone regrowth in a non-surgically treated individual.

## ACKNOWLEDGMENTS

GJA was supported by a National Health and Medical Research Council of Australia R Douglas Wright Fellowship. The authors thank Dr. Masakazu Kogawa, University of Adelaide, for his critical comments.

## REFERENCES

- 1 Harris WH, Schiller AL, Scholler JM, Freiberg RA, Scott R. Extensive localized bone resorption in the femur following total hip replacement. *J Bone Joint Surg Am* 1976; **58**: 612-618
- 2 Wang ML, Sharkey PF, Tuan RS. Particle bioreactivity and wear-mediated osteolysis. *J Arthroplasty* 2004; **19**: 1028-1038
- 3 Total hip replacement. *NIH Consensus Statement* 1994; **12**: 1-31
- 4 Skoglund B, Holmertz J, Aspenberg P. Systemic and local ibandronate enhance screw fixation. *J Orthop Res* 2004; **22**: 1108-1113
- 5 McEvoy A, Jeyam M, Ferrier G, Evans CE, Andrew JG. Synergistic effect of particles and cyclic pressure on cytokine production in human monocyte/macrophages: proposed role in periprosthetic osteolysis. *Bone* 2002; **30**: 171-177
- 6 Haynes DR, Rogers SD, Hay S, Percy MJ, Howie DW. The differences in toxicity and release of bone-resorbing mediators induced by titanium and cobalt-chromium-alloy wear particles. *J Bone Joint Surg Am* 1993; **75**: 825-834
- 7 Kaufman AM, Alabre CI, Rubash HE, Shanbhag AS. Human macrophage response to UHMWPE, TiAlV, CoCr, and alumina particles: analysis of multiple cytokines using protein arrays. *J Biomed Mater Res A* 2008; **84**: 464-474
- 8 Jones LC, Frondoza C, Hungerford DS. Effect of PMMA particles and movement on an implant interface in a canine


- model. *J Bone Joint Surg Br* 2001; **83**: 448-458
- 9 **Revell PA**, Weightman B, Freeman MA, Roberts BV. The production and biology of polyethylene wear debris. *Arch Orthop Trauma Surg* 1978; **91**: 167-181
  - 10 **Looney RJ**, Boyd A, Totterman S, Seo GS, Tamez-Pena J, Campbell D, Novotny L, Olcott C, Martell J, Hayes FA, O'Keefe RJ, Schwarz EM. Volumetric computerized tomography as a measurement of periprosthetic acetabular osteolysis and its correlation with wear. *Arthritis Res* 2002; **4**: 59-63
  - 11 **Kim KJ**, Kobayashi Y, Itoh T. Osteolysis model with continuous infusion of polyethylene particles. *Clin Orthop Relat Res* 1998; 46-52
  - 12 **Howie DW**, Neale SD, Stamenkov R, McGee MA, Taylor DJ, Findlay DM. Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. *J Bone Joint Surg Am* 2007; **89**: 1818-1825
  - 13 **Gupta SK**, Chu A, Ranawat AS, Slamin J, Ranawat CS. Osteolysis after total knee arthroplasty. *J Arthroplasty* 2007; **22**: 787-799
  - 14 **Ingram RT**, Bonde SK, Riggs BL, Fitzpatrick LA. Effects of transforming growth factor beta (TGF beta) and 1,25 dihydroxyvitamin D3 on the function, cytochemistry and morphology of normal human osteoblast-like cells. *Differentiation* 1994; **55**: 153-163
  - 15 **Matthews JB**, Besong AA, Green TR, Stone MH, Wroblewski BM, Fisher J, Ingham E. Evaluation of the response of primary human peripheral blood mononuclear phagocytes to challenge with in vitro generated clinically relevant UHMWPE particles of known size and dose. *J Biomed Mater Res* 2000; **52**: 296-307
  - 16 **Sieving A**, Wu B, Mayton L, Nasser S, Wooley PH. Morphological characteristics of total joint arthroplasty-derived ultra-high molecular weight polyethylene (UHMWPE) wear debris that provoke inflammation in a murine model of inflammation. *J Biomed Mater Res A* 2003; **64**: 457-464
  - 17 **Gomez-Barrena E**, Puertolas JA, Munuera L, Konttinen YT. Update on UHMWPE research: from the bench to the bedside. *Acta Orthop* 2008; **79**: 832-840
  - 18 **Glyn-Jones S**, Isaac S, Hauptfleisch J, McLardy-Smith P, Murray DW, Gill HS. Does highly cross-linked polyethylene wear less than conventional polyethylene in total hip arthroplasty? A double-blind, randomized, and controlled trial using roentgen stereophotogrammetric analysis. *J Arthroplasty* 2008; **23**: 337-343
  - 19 **Thomas GER**, Simpson DJ, Mehmood S, Taylor A, McLardy-Smith P, Gill HS, Murray DW, Glyn-Jones S. The seven-year wear of highly cross-linked polyethylene in total hip arthroplasty: a double-blind, randomized controlled trial using radiostereometric analysis. *J Bone Joint Surg Am* 2011; **93**: 716-22
  - 20 **Kurtz SM**, Gawel HA, Patel JD. History and systematic review of wear and osteolysis outcomes for first-generation highly crosslinked polyethylene. *Clin Orthop Relat Res* 2011; **469**: 2262-2277
  - 21 **Engh CA**, Stepniewski AS, Ginn SD, Beykirch SE, Sychterz-Terefenko CJ, Hopper RH, Engh CA. A randomized prospective evaluation of outcomes after total hip arthroplasty using cross-linked marathon and non-cross-linked Enduron polyethylene liners. *J Arthroplasty* 2006; **21**: 17-25
  - 22 **Leung SB**, Egawa H, Stepniewski A, Beykirch S, Engh CA, Engh CA. Incidence and volume of pelvic osteolysis at early follow-up with highly cross-linked and noncross-linked polyethylene. *J Arthroplasty* 2007; **22**: 134-139
  - 23 **Mall NA**, Nunley RM, Zhu JJ, Maloney WJ, Barrack RL, Clohisy JC. The incidence of acetabular osteolysis in young patients with conventional versus highly crosslinked polyethylene. *Clin Orthop Relat Res* 2011; **469**: 372-381
  - 24 **Schroder DT**, Kelly NH, Wright TM, Parks ML. Retrieved highly crosslinked UHMWPE acetabular liners have similar wear damage as conventional UHMWPE. *Clin Orthop Relat Res* 2011; **469**: 387-394
  - 25 **Endo M**, Tipper JL, Barton DC, Stone MH, Ingham E, Fisher J. Comparison of wear, wear debris and functional biological activity of moderately crosslinked and non-crosslinked polyethylenes in hip prostheses. *Proc Inst Mech Eng H* 2002; **216**: 111-122
  - 26 **Illgen RL**, Forsythe TM, Pike JW, Laurent MP, Blanchard CR. Highly crosslinked vs conventional polyethylene particles—an in vitro comparison of biologic activities. *J Arthroplasty* 2008; **23**: 721-731
  - 27 **Bi Y**, Seabold JM, Kaar SG, Ragab AA, Goldberg VM, Anderson JM, Greenfield EM. Adherent endotoxin on orthopedic wear particles stimulates cytokine production and osteoclast differentiation. *J Bone Miner Res* 2001; **16**: 2082-2091
  - 28 **Takagi M**. Bone-implant interface biology: foreign body reaction and periprosthetic osteolysis in artificial hip joints. *J Clin Exp Hematopathol* 2001; **41**: 81-87
  - 29 **Takagi M**, Santavirta S, Ida H, Ishii M, Takei I, Niissalo S, Ogino T, Konttinen YT. High-turnover periprosthetic bone remodeling and immature bone formation around loose cemented total hip joints. *J Bone Miner Res* 2001; **16**: 79-88
  - 30 **Jacobs JJ**, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. *Clin Orthop Relat Res* 2001; 71-77
  - 31 **Haynes DR**, Crotti TN, Zreiqat H. Regulation of osteoclast activity in peri-implant tissues. *Biomaterials* 2004; **25**: 4877-4885
  - 32 **Goodman SB**, Lind M, Song Y, Smith RL. In vitro, in vivo, and tissue retrieval studies on particulate debris. *Clin Orthop Relat Res* 1998; 25-34
  - 33 **McGee MA**, Howie DW, Neale SD, Haynes DR, Pearcy MJ. The role of polyethylene wear in joint replacement failure. *Proc Inst Mech Eng H* 1997; **211**: 65-72
  - 34 **Crotti TN**, Smith MD, Findlay DM, Zreiqat H, Ahern MJ, Weedon H, Hatzinikolous G, Capone M, Holding C, Haynes DR. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. *Biomaterials* 2004; **25**: 565-573
  - 35 **Kobayashi A**, Freeman MA, Bonfield W, Kadoya Y, Yamac T, Al-Saffar N, Scott G, Revell PA. Number of polyethylene particles and osteolysis in total joint replacements. A quantitative study using a tissue-digestion method. *J Bone Joint Surg Br* 1997; **79**: 844-848
  - 36 **Takagi M**, Santavirta S, Ida H, Ishii M, Akimoto K, Saotome K, Konttinen YT. The membrane-type-matrix metalloproteinase/matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 system in periprosthetic connective-tissue remodeling in loose total-hip prostheses. *Lab Invest* 1998; **78**: 735-742
  - 37 **Takagi M**, Santavirta S, Ida H, Ishii M, Mandelin J, Konttinen YT. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. *Clin Orthop Relat Res* 1998; 35-45
  - 38 **Konttinen YT**, Takagi M, Mandelin J, Lassus J, Salo J, Ainala M, Li TF, Virtanen I, Liljestrom M, Sakai H, Kobayashi Y, Sorsa T, Lappalainen R, Demulder A, Santavirta S. Acid attack and cathepsin K in bone resorption around total hip replacement prosthesis. *J Bone Miner Res* 2001; **16**: 1780-1786
  - 39 **Goodman SB**, Huie P, Song Y, Schurman D, Maloney W, Woolson S, Sibley R. Cellular profile and cytokine production at prosthetic interfaces. Study of tissues retrieved from revised hip and knee replacements. *J Bone Joint Surg Br* 1998; **80**: 531-539
  - 40 **Holding CA**, Findlay DM, Stamenkov R, Neale SD, Lucas H, Dharmapatri AS, Callary SA, Shrestha KR, Atkins GJ, Howie DW, Haynes DR. The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. *Biomaterials* 2006; **27**: 5212-5219
  - 41 **al Saffar N**, Revell PA. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: a

- potential role in osteolysis. *Br J Rheumatol* 1994; **33**: 309-316
- 42 **Takei I**, Takagi M, Ida H, Ogino T, Santavirta S, Konttinen YT. High macrophage-colony stimulating factor levels in synovial fluid of loose artificial hip joints. *J Rheumatol* 2000; **27**: 894-899
- 43 **Nakashima Y**, Sun DH, Trindade MC, Chun LE, Song Y, Goodman SB, Schurman DJ, Maloney WJ, Smith RL. Induction of macrophage C-C chemokine expression by titanium alloy and bone cement particles. *J Bone Joint Surg Br* 1999; **81**: 155-162
- 44 **Asagiri M**, Takayanagi H. The molecular understanding of osteoclast differentiation. *Bone* 2007; **40**: 251-264
- 45 **Lam J**, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. *J Clin Invest* 2000; **106**: 1481-1488
- 46 **Ma T**, Huang Z, Ren PG, McCally R, Lindsey D, Smith RL, Goodman SB. An in vivo murine model of continuous intramedullary infusion of polyethylene particles. *Biomaterials* 2008; **29**: 3738-3742
- 47 **Ingham E**, Fisher J. The role of macrophages in osteolysis of total joint replacement. *Biomaterials* 2005; **26**: 1271-1286
- 48 **Ren PG**, Huang Z, Ma T, Biswal S, Smith RL, Goodman SB. Surveillance of systemic trafficking of macrophages induced by UHMWPE particles in nude mice by noninvasive imaging. *J Biomed Mater Res A* 2010; **94**: 706-711
- 49 **Horowitz SM**, Gonzales JB. Effects of polyethylene on macrophages. *J Orthop Res* 1997; **15**: 50-56
- 50 **Ren W**, Markel DC, Schwendener R, Ding Y, Wu B, Wooley PH. Macrophage depletion diminishes implant-wear-induced inflammatory osteolysis in a mouse model. *J Biomed Mater Res A* 2008; **85**: 1043-1051
- 51 **Haynes DR**, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, Findlay DM. The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. *J Bone Joint Surg Br* 2001; **83**: 902-911
- 52 **Neale SD**, Fujikawa Y, Sabokbar A, Gundle R, Murray DW, Graves SE, Howie DW, Athanasou NA. Human bone-derived cells support formation of human osteoclasts from arthroplasty-derived cells in vitro. *J Bone Joint Surg Br* 2000; **82**: 892-900
- 53 **Sabokbar A**, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. *J Orthop Res* 2003; **21**: 73-80
- 54 **Yasuda H**, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998; **95**: 3597-3602
- 55 **Hofbauer LC**, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. *J Bone Miner Res* 2000; **15**: 2-12
- 56 **Quinn JM**, Horwood NJ, Elliott J, Gillespie MT, Martin TJ. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation. *J Bone Miner Res* 2000; **15**: 1459-1466
- 57 **Mandelin J**, Li TF, Hukkanen M, Liljeström M, Salo J, Santavirta S, Konttinen YT. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and cathepsin K. *J Rheumatol* 2005; **32**: 713-720
- 58 **Atkins GJ**, Welldon KJ, Holding CA, Haynes DR, Howie DW, Findlay DM. The induction of a catabolic phenotype in human primary osteoblasts and osteocytes by polyethylene particles. *Biomaterials* 2009; **30**: 3672-3681
- 59 **Horwood NJ**, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. *Biochem Biophys Res Commun* 1999; **265**: 144-150
- 60 **Crotti T**, Smith MD, Hirsch R, Soukoulis S, Weedon H, Capone M, Ahern MJ, Haynes D. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. *J Periodontal Res* 2003; **38**: 380-387
- 61 **Crotti TN**, Smith MD, Weedon H, Ahern MJ, Findlay DM, Kraan M, Tak PP, Haynes DR. Receptor activator NF-kappaB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients: semiquantitative and quantitative analysis. *Ann Rheum Dis* 2002; **61**: 1047-1054
- 62 **Haynes DR**, Barg E, Crotti TN, Holding C, Weedon H, Atkins GJ, Zannettino A, Ahern MJ, Coleman M, Roberts-Thomson PJ, Kraan M, Tak PP, Smith MD. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. *Rheumatology (Oxford)* 2003; **42**: 123-134
- 63 **Masui T**, Sakano S, Hasegawa Y, Warashina H, Ishiguro N. Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles. *Biomaterials* 2005; **26**: 1695-1702
- 64 **Findlay DM**, Haynes DR. Mechanisms of bone loss in rheumatoid arthritis. *Mod Rheumatol* 2005; **15**: 232-240
- 65 **Vincent C**, Kogawa M, Findlay DM, Atkins GJ. The generation of osteoclasts from RAW 264.7 precursors in defined, serum-free conditions. *J Bone Miner Metab* 2009; **27**: 114-119
- 66 **Goodman SB**, Ma T. Cellular chemotaxis induced by wear particles from joint replacements. *Biomaterials* 2010; **31**: 5045-5050
- 67 **Gallo J**, Raska M, Mrázek F, Petrek M. Bone remodeling, particle disease and individual susceptibility to periprosthetic osteolysis. *Physiol Res* 2008; **57**: 339-349
- 68 **Martínez ME**, Medina S, del Campo MT, García JA, Rodrigo A, Munuera L. Effect of polyethylene particles on human osteoblastic cell growth. *Biomaterials* ; **19**: 183-187
- 69 **Dean DD**, Schwartz Z, Liu Y, Blanchard CR, Agrawal CM, Mabrey JD, Sylvia VL, Lohmann CH, Boyan BD. The effect of ultra-high molecular weight polyethylene wear debris on MG63 osteosarcoma cells in vitro. *J Bone Joint Surg Am* 1999; **81**: 452-461
- 70 **Chiu R**, Ma T, Smith RL, Goodman SB. Ultrahigh molecular weight polyethylene wear debris inhibits osteoprogenitor proliferation and differentiation in vitro. *J Biomed Mater Res A* 2009; **89**: 242-247
- 71 **Vermes C**, Chandrasekaran R, Jacobs JJ, Galante JO, Roebuck KA, Glant TT. The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. *J Bone Joint Surg Am* 2001; **83-A**: 201-211
- 72 **Rodrigo AM**, Martínez ME, Saldaña L, Vallés G, Martínez P, González-Carrasco JL, Cordero J, Munuera L. Effects of polyethylene and alpha-alumina particles on IL-6 expression and secretion in primary cultures of human osteoblastic cells. *Biomaterials* 2002; **23**: 901-908
- 73 **Granchi D**, Ciapetti G, Amato I, Pagani S, Cenni E, Savarino L, Avnet S, Peris JL, Pellacani A, Baldini N, Giunti A. The influence of alumina and ultra-high molecular weight polyethylene particles on osteoblast-osteoclast cooperation. *Biomaterials* 2004; **25**: 4037-4045
- 74 **Lohmann CH**, Dean DD, Bonewald LF, Schwartz Z, Boyan BD. Nitric oxide and prostaglandin E2 production in response to ultra-high molecular weight polyethylene particles depends on osteoblast maturation state. *J Bone Joint Surg Am* 2002; **84-A**: 411-419
- 75 **Atkins GJ**, Welldon KJ, Wijenayaka AR, Bonewald LF, Findlay DM. Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. *Am J Physiol Cell Physiol* 2009; **297**: C1358-C1367
- 76 **Elfick AP**, Green SM, McCaskie AW, Birch MA. Opsoniza-



- tion of polyethylene wear particles regulates macrophage and osteoblast responses in vitro. *J Biomed Mater Res B Appl Biomater* 2004; **71**: 244-251
- 77 **Maitra R**, Clement CC, Scharf B, Crisi GM, Chitta S, Paget D, Purdue PE, Cobelli N, Santambrogio L. Endosomal damage and TLR2 mediated inflammasome activation by alkane particles in the generation of aseptic osteolysis. *Mol Immunol* 2009; **47**: 175-184
  - 78 **Hao HN**, Zheng B, Nasser S, Ren W, Latteier M, Wooley P, Morawa L. The roles of monocytic heat shock protein 60 and Toll-like receptors in the regional inflammation response to wear debris particles. *J Biomed Mater Res A* 2010; **92**: 1373-1381
  - 79 **Landesberg R**, Eisig S, Fennoy I, Siris E. Alternative indications for bisphosphonate therapy. *J Oral Maxillofac Surg* 2009; **67**: 27-34
  - 80 **Millett PJ**, Allen MJ, Bostrom MP. Effects of alendronate on particle-induced osteolysis in a rat model. *J Bone Joint Surg Am* 2002; **84-A**: 236-249
  - 81 **Shanbhag AS**, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. *Clin Orthop Relat Res* 1997; 33-43
  - 82 **Iwase M**, Kim KJ, Kobayashi Y, Itoh M, Itoh T. A novel bisphosphonate inhibits inflammatory bone resorption in a rat osteolysis model with continuous infusion of polyethylene particles. *J Orthop Res* 2002; **20**: 499-505
  - 83 **O'Hara LJ**, Nivbrant B, Röhrli S. Cross-linked polyethylene and bisphosphonate therapy for osteolysis in total hip arthroplasty: a case report. *J Orthop Surg (Hong Kong)* 2004; **12**: 114-121
  - 84 **von Knoch F**, Heckelei A, Wedemeyer C, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraaber S, Henschke F, Löer F, von Knoch M. Suppression of polyethylene particle-induced osteolysis by exogenous osteoprotegerin. *J Biomed Mater Res A* 2005; **75**: 288-294
  - 85 **Goater JJ**, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. *J Orthop Res* 2002; **20**: 169-173
  - 86 **Childs LM**, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB: Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. *J Bone Miner Res* 2002; **17**: 192-199
  - 87 **Goodman S**, Trindade M, Ma T, Lee M, Wang N, Ikenou T, Matsuura I, Miyanishi K, Fox N, Regula D, Genovese M, Klein J, Bloch D, Smith RL. Modulation of bone ingrowth and tissue differentiation by local infusion of interleukin-10 in the presence of ultra-high molecular weight polyethylene (UHMWPE) wear particles. *J Biomed Mater Res A* 2003; **65**: 43-50
  - 88 **Childs LM**, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. *J Bone Joint Surg Am* 2001; **83-A**: 1789-1797
  - 89 **Schwarz EM**, Campbell D, Totterman S, Boyd A, O'Keefe RJ, Looney RJ. Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo. *J Orthop Res* 2003; **21**: 1049-1055
  - 90 **Dormán G**, Cseh S, Hajdú I, Barna L, Kónya D, Kupai K, Kovács L, Ferdinandy P. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. *Drugs* 2010; **70**: 949-964
  - 91 **Schwarz EM**. What potential biologic treatments are available for osteolysis? *J Am Acad Orthop Surg* 2008; **16** Suppl 1: S72-S75
  - 92 **Zhou X**, Zhang P, Zhang C, Zhu Z. Promotion of bone formation by naringin in a titanium particle-induced diabetic murine calvarial osteolysis model. *J Orthop Res* 2010; **28**: 451-456
  - 93 **von Knoch F**, Wedemeyer C, Heckelei A, Saxler G, Hilken G, Brankamp J, Sterner T, Landgraaber S, Henschke F, Löer F, von Knoch M. Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis. *Biomaterials* 2005; **26**: 5783-5789
  - 94 **Paszty C**, Turner CH, Robinson MK. Sclerostin: a gem from the genome leads to bone-building antibodies. *J Bone Miner Res* 2010; **25**: 1897-1904

S- Editor Yang XC L- Editor Roemmele A E- Editor Zheng XM



## ACKNOWLEDGMENTS

### Acknowledgments to reviewers of *World Journal of Orthopedics*

Many reviewers have contributed their expertise and time to the peer review, a critical process to ensure the quality of *World Journal of Orthopedics*. The editors and authors of the articles submitted to the journal are grateful to the following reviewers for evaluating the articles (including those published in this issue and those rejected for this issue) during the last editing time period.

**Charalampos Zalavras, Dr.**, Department of Orthopaedic Surgery, University of Southern California, 1200 N State St, GNH 3900, Los Angeles, CA 90033, United States

**Konstantin I Momot, PhD**, Queensland University of Technology, GPO Box 2434, Brisbane, Qld 4001, Australia

**Nuria Vilaboa, Dr.**, Hospital Universitario La-Paz-IdiPAZ Edificio de I+D Paseo de La Castellana 261, 28046 Madrid, Spain

**Richard Kremer, Dr.**, McGill University Health Center, 687 Pine Ave West Rm H.467, Montreal H3A1A1, Canada

**Bart C H van der Wal, MD, PhD**, Department of Orthopaedic Surgery and Traumatology, Meander Medical Center, Ringweg Randenbroek 110, Amersfoort, 3816 CP, Netherlands

**Hisataka Yasuda, Dr.**, Oriental Yeast Co., Ltd. Bioindustry division, 3-6-10 Azusawa, Itabashi-ku, Tokyo 174-8505, Japan

**Antonio Herrera, Professor**, Orthopaedic Surgery and Traumatology Miguel Servet University Hospital, Avenue Isabel la Catolican1, Zaragoza 50009, Spain



## Events Calendar 2011

January 16-20, 2011  
Combined 4th International  
Conference of the Saudi Orthopaedic  
Association & SICOT Trainee Day,  
Abha, Saudi Arabia

January 24-27, 2011  
7th Middle East Orthopaedics  
Conference 2011, Dubai International  
Convention Centre, Dubai,  
Saudi Arabia

January 28-30, 2011  
National Orthopedic Conference  
2011, San Francisco, California,  
United States

February 15-19, 2011  
American Academy of Orthopaedic  
Surgeons, San Diego, CA,  
United States

February 16-20, 2011  
2011 Annual Meeting of the American  
Academy of Orthopaedic Surgeons,  
San Diego, CA, United States

February 19, 2011  
Pediatric Orthopaedic Society of  
North America Specialty Day, San  
Diego, CA, United States

March 09-11, 2011  
Annual London Imperial Spine  
Course, London, United Kingdom

March 21-25, 2011  
31st Caribbean Orthopaedic  
Meeting, Anse Marcel, Saint Martin

March 28-April 02, 2011  
The Association of Children's  
Prosthetic-Orthotic Clinics 2011  
Annual Meeting, Park City, UT,  
United States

April 01-04, 2011  
Ain Shams 2nd Orthopaedic  
intensive course (Orthopaedics from  
A to Z), Cairo, Egypt

April 20-22, 2011  
IMUKA 2011: Masterclass in  
Arthroscopy and Related Surgery,  
Maastricht, Netherlands

May 11-14, 2011  
2011 POSNA Annual Meeting,  
Montreal, Quebec, Canada

May 12-15, 2011  
84th Annual Meeting of the  
Japanese Orthopaedic Association,  
Yokohama, Japan

May 15-19, 2011  
8th Biennial ISAKOS Congress  
(International Society of  
Arthroscopy, Knee Surgery and  
Orthopaedic Sports Medicine), Rio  
de Janeiro, Brazil

May 25-28, 2011  
16th Pan Arab Orthopedic  
Association Congress & 27th  
SOTCOT Congress, Tunis, Tunisia

June 01-04, 2011  
12th EFORT Congress in cooperation  
with the Danish Orthopaedic  
Association (European Federation

of National Associations of  
Orthopaedics and Traumatology),  
Copenhagen, Denmark

June 08-12, 2011  
2011 ABJS Annual Meeting  
(Association of Bone and Joint  
Surgeons), Dublin, Ireland

June 15-18, 2011  
11th Annual Meeting of the  
International Society for Computer  
Assisted Orthopaedic Surgery,  
London, United Kingdom

July 07-09, 2011  
66th Annual Meeting of the  
Canadian Orthopaedic Association,  
St. John's, Newfoundland and  
Labrador, Canada

July 13-16, 2011  
18th International Meeting on  
Advanced Spine Techniques,  
Copenhagen, Denmark

July 22-24, 2011  
Sri Sathya Sai International  
Orthopaedic Conference- 2011  
On Pelvis And Lower Extremity  
Trauma", Sri Sathya Sai Institute  
of Higher Medical Sciences,  
Prasanthigram, Puttaparthi, Andhra  
Pradesh, India

July 25-28, 2011  
2011 Update in Orthopaedics, Grand  
Wailea Hotel Resort & Spa, Wailea,  
Maui, Hawaii, United States

September 06-09, 2011

SICOT 2011 XXV Triennial World  
Congress, Prague, Czech Republic

September 13-16, 2011  
BOA/IOA Combined  
Meeting (British Orthopaedic  
Association & Irish Orthopaedic  
Association), Dublin, Ireland

September 14-17, 2011  
23rd SECEC-ESSSE Congress  
(European Society for Surgery of  
the Shoulder and the Elbow), Lyon,  
France

September 14-17, 2011  
46th SRS Annual Meeting &  
Course (Scoliosis Research Society),  
Louisville, Kentucky, United States

September 15-18, 2011  
2011 World Congress on  
Osteoarthritis, San Diego, California  
92167, United States

September 21-23, 2011  
HIP IMPROVEMENTS AND  
PROCEEDINGS, Toulouse, France

October 25-28, 2011  
DKOU 2011-Deutscher Kongress  
für Orthopädie und Unfallchirurgie,  
Berlin, Germany

November 7-11, 2011  
86ème Réunion Annuelle SOFCOT,  
Paris, France

December 12-15, 2011  
EOA 63rd Annual International  
Conference, Cairo, Egypt



## INSTRUCTIONS TO AUTHORS

### GENERAL INFORMATION

*World Journal of Orthopedics* (World J Orthop, WJO, online ISSN 2218-5836, DOI: 10.5312) is a monthly peer-reviewed, online, open-access (OA), journal supported by an editorial board consisting of 245 experts in orthopedics from 30 countries.

The biggest advantage of the OA model is that it provides free, full-text articles in PDF and other formats for experts and the public without registration, which eliminates the obstacle that traditional journals possess and usually delays the speed of the propagation and communication of scientific research results. The open access model has been proven to be a true approach that may achieve the ultimate goal of the journals, i.e. the maximization of the value to the readers, authors and society.

#### Maximization of personal benefits

The role of academic journals is to exhibit the scientific levels of a country, a university, a center, a department, and even a scientist, and build an important bridge for communication between scientists and the public. As we all know, the significance of the publication of scientific articles lies not only in disseminating and communicating innovative scientific achievements and academic views, as well as promoting the application of scientific achievements, but also in formally recognizing the "priority" and "copyright" of innovative achievements published, as well as evaluating research performance and academic levels. So, to realize these desired attributes of WJO and create a well-recognized journal, the following four types of personal benefits should be maximized. The maximization of personal benefits refers to the pursuit of the maximum personal benefits in a well-considered optimal manner without violation of the laws, ethical rules and the benefits of others. (1) Maximization of the benefits of editorial board members: The primary task of editorial board members is to give a peer review of an unpublished scientific article via online office system to evaluate its innovativeness, scientific and practical values and determine whether it should be published or not. During peer review, editorial board members can also obtain cutting-edge information in that field at first hand. As leaders in their field, they have priority to be invited to write articles and publish commentary articles. We will put peer reviewers' names and affiliations along with the article they reviewed in the journal to acknowledge their contribution; (2) Maximization of the benefits of authors: Since WJO is an open-access journal, readers around the world can immediately download and read, free of charge, high-quality, peer-reviewed articles from WJO official website, thereby realizing the goals and significance of the communication between authors and peers as well as public reading; (3) Maximization of the benefits of readers: Readers can read or use, free of charge, high-quality peer-reviewed articles without any limits, and cite the arguments, viewpoints, concepts, theories, methods, results, conclusion or facts and data of pertinent literature so as to validate the innovativeness, scientific and practical values of their own research achievements, thus ensuring that their articles have novel arguments or viewpoints, solid evidence and correct conclusion; and (4) Maximization of the benefits of employees: It is an iron law that a first-class journal is unable to exist without first-class editors, and only first-class editors can create a first-class academic journal. We insist on strengthening our team cultivation and construction so that every employee, in an open, fair and transparent environment, could contribute their wisdom to edit and publish high-quality articles, thereby realizing the maximization of the personal benefits

of editorial board members, authors and readers, and yielding the greatest social and economic benefits.

#### Aims and scope

The aim of WJO is to report rapidly new theories, methods and techniques for prevention, diagnosis, treatment, rehabilitation and nursing in the field of orthopedics. WJO covers diagnostic imaging, arthroscopy, evidence-based medicine, epidemiology, nursing, sports medicine, therapy of bone and spinal diseases, bone trauma, osteoarthritis, bone tumors and osteoporosis, minimally invasive therapy, traditional medicine, and integrated Chinese and Western medicine. The journal also publishes original articles and reviews that report the results of applied and basic research in fields related to orthopedics, such as immunology, physiopathology, cell biology, pharmacology, medical genetics, and pharmacology of Chinese herbs.

#### Columns

The columns in the issues of WJO will include: (1) Editorial: To introduce and comment on major advances and developments in the field; (2) Frontier: To review representative achievements, comment on the state of current research, and propose directions for future research; (3) Topic Highlight: This column consists of three formats, including (A) 10 invited review articles on a hot topic, (B) a commentary on common issues of this hot topic, and (C) a commentary on the 10 individual articles; (4) Observation: To update the development of old and new questions, highlight unsolved problems, and provide strategies on how to solve the questions; (5) Guidelines for Basic Research: To provide Guidelines for basic research; (6) Guidelines for Clinical Practice: To provide guidelines for clinical diagnosis and treatment; (7) Review: To review systematically progress and unresolved problems in the field, comment on the state of current research, and make suggestions for future work; (8) Original Articles: To report innovative and original findings in orthopedics; (9) Brief Articles: To briefly report the novel and innovative findings in orthopedics; (10) Case Report: To report a rare or typical case; (11) Letters to the Editor: To discuss and make reply to the contributions published in WJO, or to introduce and comment on a controversial issue of general interest; (12) Book Reviews: To introduce and comment on quality monographs of orthopedics; and (13) Guidelines: To introduce consensus and guidelines reached by international and national academic authorities worldwide on the research orthopedics.

#### Name of journal

*World Journal of Orthopedics*

#### ISSN

ISSN 2218-5836 (online)

#### Indexed and Abstracted in

Digital Object Identifier and Directory of Open Access Journals

#### Published by

Baishideng Publishing Group Co., Limited

### SPECIAL STATEMENT

All articles published in this journal represent the viewpoints of the authors except where indicated otherwise.

### Biostatistical editing

Statistical review is performed after peer review. We invite an expert in Biomedical Statistics from to evaluate the statistical method used in the paper, including *t*-test (group or paired comparisons), chi-squared test, Riddit, probit, logit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance, analysis of covariance, *etc.* The reviewing points include: (1) Statistical methods should be described when they are used to verify the results; (2) Whether the statistical techniques are suitable or correct; (3) Only homogeneous data can be averaged. Standard deviations are preferred to standard errors. Give the number of observations and subjects (*n*). Losses in observations, such as drop-outs from the study should be reported; (4) Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney); and (5) The word 'significantly' should be replaced by its synonyms (if it indicates extent) or the *P* value (if it indicates statistical significance).

### Conflict-of-interest statement

In the interests of transparency and to help reviewers assess any potential bias, *WJO* requires authors of all papers to declare any competing commercial, personal, political, intellectual, or religious interests in relation to the submitted work. Referees are also asked to indicate any potential conflict they might have reviewing a particular paper. Before submitting, authors are suggested to read "Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Conflicts of Interest" from International Committee of Medical Journal Editors (ICMJE), which is available at: [http://www.icmje.org/ethical\\_4conflicts.html](http://www.icmje.org/ethical_4conflicts.html).

Sample wording: [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description].

### Statement of informed consent

Manuscripts should contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee or it should be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted. Authors should also draw attention to the Code of Ethics of the World Medical Association (Declaration of Helsinki, 1964, as revised in 2004).

### Statement of human and animal rights

When reporting the results from experiments, authors should follow the highest standards and the trial should conform to Good Clinical Practice (for example, US Food and Drug Administration Good Clinical Practice in FDA-Regulated Clinical Trials; UK Medicines Research Council Guidelines for Good Clinical Practice in Clinical Trials) and/or the World Medical Association Declaration of Helsinki. Generally, we suggest authors follow the lead investigator's national standard. If doubt exists whether the research was conducted in accordance with the above standards, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study.

Before submitting, authors should make their study approved by the relevant research ethics committee or institutional review board. If human participants were involved, manuscripts must be accompanied by a statement that the experiments were undertaken with the understanding and appropriate informed consent of each. Any personal item or information will not be published without explicit consents from the involved patients. If experimental animals were used, the materials and methods (experimental procedures) section must clearly indicate that appropriate measures were taken to minimize

pain or discomfort, and details of animal care should be provided.

## SUBMISSION OF MANUSCRIPTS

Manuscripts should be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Number all pages consecutively, and start each of the following sections on a new page: Title Page, Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgements, References, Tables, Figures, and Figure Legends. Neither the editors nor the publisher are responsible for the opinions expressed by contributors. Manuscripts formally accepted for publication become the permanent property of Baishideng Publishing Group Co., Limited, and may not be reproduced by any means, in whole or in part, without the written permission of both the authors and the publisher. We reserve the right to copy-edit and put onto our website accepted manuscripts. Authors should follow the relevant guidelines for the care and use of laboratory animals of their institution or national animal welfare committee. For the sake of transparency in regard to the performance and reporting of clinical trials, we endorse the policy of the ICMJE to refuse to publish papers on clinical trial results if the trial was not recorded in a publicly-accessible registry at its outset. The only register now available, to our knowledge, is <http://www.clinicaltrials.gov> sponsored by the United States National Library of Medicine and we encourage all potential contributors to register with it. However, in the case that other registers become available you will be duly notified. A letter of recommendation from each author's organization should be provided with the contributed article to ensure the privacy and secrecy of research is protected.

Authors should retain one copy of the text, tables, photographs and illustrations because rejected manuscripts will not be returned to the author(s) and the editors will not be responsible for loss or damage to photographs and illustrations sustained during mailing.

### Online submissions

Manuscripts should be submitted through the Online Submission System at: <http://www.wjgnet.com/2218-5836/office>. Authors are highly recommended to consult the ONLINE INSTRUCTIONS TO AUTHORS ([http://www.wjgnet.com/2218-5836/g\\_info\\_20100722172650.htm](http://www.wjgnet.com/2218-5836/g_info_20100722172650.htm)) before attempting to submit online. For assistance, authors encountering problems with the Online Submission System may send an email describing the problem to [wjo@wjgnet.com](mailto:wjo@wjgnet.com), or by telephone: +86-10-85381892. If you submit your manuscript online, do not make a postal contribution. Repeated online submission for the same manuscript is strictly prohibited.

## MANUSCRIPT PREPARATION

All contributions should be written in English. All articles must be submitted using word-processing software. All submissions must be typed in 1.5 line spacing and 12 pt. Book Antiqua with ample margins. Style should conform to our house format. Required information for each of the manuscript sections is as follows:

### Title page

**Title:** Title should be less than 12 words.

**Running title:** A short running title of less than 6 words should be provided.

**Authorship:** Authorship credit should be in accordance with the standard proposed by International Committee of Medical Journal Editors, based on (1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; (2) drafting the article or revising it critically for important intellectual content; and (3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

**Institution:** Author names should be given first, then the complete name of institution, city, province and postcode. For ex-



ample, Xu-Chen Zhang, Li-Xin Mei, Department of Pathology, Chengde Medical College, Chengde 067000, Hebei Province, China. One author may be represented from two institutions, for example, George Sgourakis, Department of General, Visceral, and Transplantation Surgery, Essen 45122, Germany; George Sgourakis, 2nd Surgical Department, Korgialenio-Benakio Red Cross Hospital, Athens 15451, Greece

**Author contributions:** The format of this section should be: Author contributions: Wang CL and Liang L contributed equally to this work; Wang CL, Liang L, Fu JF, Zou CC, Hong F and Wu XM designed the research; Wang CL, Zou CC, Hong F and Wu XM performed the research; Xue JZ and Lu JR contributed new reagents/analytic tools; Wang CL, Liang L and Fu JF analyzed the data; and Wang CL, Liang L and Fu JF wrote the paper.

**Supportive foundations:** The complete name and number of supportive foundations should be provided, e.g. Supported by National Natural Science Foundation of China, No. 30224801

**Correspondence to:** Only one corresponding address should be provided. Author names should be given first, then author title, affiliation, the complete name of institution, city, postcode, province, country, and email. All the letters in the email should be in lower case. A space interval should be inserted between country name and email address. For example, Montgomery Bissell, MD, Professor of Medicine, Chief, Liver Center, Gastroenterology Division, University of California, Box 0538, San Francisco, CA 94143, United States. montgomerybissell@ucsf.edu

**Telephone and fax:** Telephone and fax should consist of +, country number, district number and telephone or fax number, e.g. Telephone: +86-10-59080039 Fax: +86-10-85381893

**Peer reviewers:** All articles received are subject to peer review. Normally, three experts are invited for each article. Decision for acceptance is made only when at least two experts recommend an article for publication. Reviewers for accepted manuscripts are acknowledged in each manuscript, and reviewers of articles which were not accepted will be acknowledged at the end of each issue. To ensure the quality of the articles published in *WJO*, reviewers of accepted manuscripts will be announced by publishing the name, title/position and institution of the reviewer in the footnote accompanying the printed article. For example, reviewers: Professor Jing-Yuan Fang, Shanghai Institute of Digestive Disease, Shanghai, Affiliated Renji Hospital, Medical Faculty, Shanghai Jiaotong University, Shanghai, China; Professor Xin-Wei Han, Department of Radiology, The First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, China; and Professor Anren Kuang, Department of Nuclear Medicine, Huaxi Hospital, Sichuan University, Chengdu, Sichuan Province, China.

### Abstract

There are unstructured abstracts (no more than 256 words) and structured abstracts (no more than 480). The specific requirements for structured abstracts are as follows:

An informative, structured abstracts of no more than 480 words should accompany each manuscript. Abstracts for original contributions should be structured into the following sections. AIM (no more than 20 words): Only the purpose should be included. Please write the aim as the form of "To investigate/study/..."; MATERIALS AND METHODS (no more than 140 words); RESULTS (no more than 294 words): You should present *P* values where appropriate and must provide relevant data to illustrate how they were obtained, e.g.  $6.92 \pm 3.86$  vs  $3.61 \pm 1.67$ ,  $P < 0.001$ ; CONCLUSION (no more than 26 words).

### Key words

Please list 5-10 key words, selected mainly from *Index Medicus*, which reflect the content of the study.

### Text

For articles of these sections, original articles and brief articles, the main text should be structured into the following sections: INTRODUCTION, MATERIALS AND METHODS, RESULTS and DISCUSSION, and should include appropriate Figures and Tables. Data should be presented in the main text or in Figures and Tables, but not in both. The main text format of these sections, editorial, topic highlight, case report, letters to the editors, can be found at: [http://www.wjgnet.com/2218-5836/g\\_info\\_list.htm](http://www.wjgnet.com/2218-5836/g_info_list.htm).

### Illustrations

Figures should be numbered as 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each figure on a separate page. Detailed legends should not be provided under the figures. This part should be added into the text where the figures are applicable. Figures should be either Photoshop or Illustrator files (in tiff, eps, jpeg formats) at high-resolution. Examples can be found at: <http://www.wjgnet.com/1007-9327/13/4520.pdf>; <http://www.wjgnet.com/1007-9327/13/4554.pdf>; <http://www.wjgnet.com/1007-9327/13/4891.pdf>; <http://www.wjgnet.com/1007-9327/13/4986.pdf>; <http://www.wjgnet.com/1007-9327/13/4498.pdf>. Keeping all elements compiled is necessary in line-art image. Scale bars should be used rather than magnification factors, with the length of the bar defined in the legend rather than on the bar itself. File names should identify the figure and panel. Avoid layering type directly over shaded or textured areas. Please use uniform legends for the same subjects. For example: Figure 1 Pathological changes in atrophic gastritis after treatment. A: ...; B: ...; C: ...; D: ...; E: ...; F: ...; G: ...*etc.* It is our principle to publish high resolution-figures for the printed and E-versions.

### Tables

Three-line tables should be numbered 1, 2, 3, *etc.*, and mentioned clearly in the main text. Provide a brief title for each table. Detailed legends should not be included under tables, but rather added into the text where applicable. The information should complement, but not duplicate the text. Use one horizontal line under the title, a second under column heads, and a third below the Table, above any footnotes. Vertical and italic lines should be omitted.

### Notes in tables and illustrations

Data that are not statistically significant should not be noted. <sup>a</sup>*P* < 0.05, <sup>b</sup>*P* < 0.01 should be noted (*P* > 0.05 should not be noted). If there are other series of *P* values, <sup>c</sup>*P* < 0.05 and <sup>d</sup>*P* < 0.01 are used. A third series of *P* values can be expressed as <sup>e</sup>*P* < 0.05 and <sup>f</sup>*P* < 0.01. Other notes in tables or under illustrations should be expressed as <sup>1</sup>F, <sup>2</sup>F, <sup>3</sup>F; or sometimes as other symbols with a superscript (Arabic numerals) in the upper left corner. In a multi-curve illustration, each curve should be labeled with ●, ○, ■, □, ▲, △, *etc.*, in a certain sequence.

### Acknowledgments

Brief acknowledgments of persons who have made genuine contributions to the manuscript and who endorse the data and conclusions should be included. Authors are responsible for obtaining written permission to use any copyrighted text and/or illustrations.

## REFERENCES

### Coding system

The author should number the references in Arabic numerals according to the citation order in the text. Put reference numbers in square brackets in superscript at the end of citation content or after the cited author's name. For citation content which is part of the narration, the coding number and square brackets should be typeset normally. For example, "Crohn's disease (CD) is associated with increased intestinal permeability<sup>[1,2]</sup>". If references are cited directly in the text, they should be put together within the text, for example, "From references<sup>[19,22-24]</sup>, we know that...".

When the authors write the references, please ensure that



## Instructions to authors

the order in text is the same as in the references section, and also ensure the spelling accuracy of the first author's name. Do not list the same citation twice.

### PMID and DOI

Pleased provide PubMed citation numbers to the reference list, e.g. PMID and DOI, which can be found at <http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed> and <http://www.crossref.org/SimpleTextQuery/>, respectively. The numbers will be used in E-version of this journal.

### Style for journal references

Authors: the name of the first author should be typed in bold-faced letters. The family name of all authors should be typed with the initial letter capitalized, followed by their abbreviated first and middle initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR). The title of the cited article and italicized journal title (journal title should be in its abbreviated form as shown in PubMed), publication date, volume number (in black), start page, and end page [PMID: 11819634 DOI: 10.3748/wjg.13.5396].

### Style for book references

Authors: the name of the first author should be typed in bold-faced letters. The surname of all authors should be typed with the initial letter capitalized, followed by their abbreviated middle and first initials. (For example, Lian-Sheng Ma is abbreviated as Ma LS, Bo-Rong Pan as Pan BR) Book title. Publication number. Publication place: Publication press, Year: start page and end page.

### Format

#### Journals

*English journal article (list all authors and include the PMID where applicable)*

- 1 **Jung EM**, Clevert DA, Schreyer AG, Schmitt S, Rennert J, Kubale R, Feuerbach S, Jung F. Evaluation of quantitative contrast harmonic imaging to assess malignancy of liver tumors: A prospective controlled two-center study. *World J Gastroenterol* 2007; **13**: 6356-6364 [PMID: 18081224 DOI: 10.3748/wjg.13.6356]

*Chinese journal article (list all authors and include the PMID where applicable)*

- 2 **Lin GZ**, Wang XZ, Wang P, Lin J, Yang FD. Immunologic effect of Jianpi Yishen decoction in treatment of Pixu-diarhoea. *Shijie Huaren Xiaohua Zazhi* 1999; **7**: 285-287

*In press*

- 3 **Tian D**, Araki H, Stahl E, Bergelson J, Kreitman M. Signature of balancing selection in Arabidopsis. *Proc Natl Acad Sci USA* 2006; In press

*Organization as author*

- 4 **Diabetes Prevention Program Research Group**. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* 2002; **40**: 679-686 [PMID: 12411462 PMID: 2516377 DOI: 10.1161/01.HYP.0000035706.28494.09]

*Both personal authors and an organization as author*

- 5 **Vallancien G**, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1, 274 European men suffering from lower urinary tract symptoms. *J Urol* 2003; **169**: 2257-2261 [PMID: 12771764 DOI: 10.1097/01.ju.0000067940.76090.73]

*No author given*

- 6 21st century heart solution may have a sting in the tail. *BMJ* 2002; **325**: 184 [PMID: 12142303 DOI: 10.1136/bmj.325.7357.184]

*Volume with supplement*

- 7 **Geraud G**, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. *Headache* 2002; **42** Suppl 2: S93-99 [PMID: 12028325 DOI: 10.1046/j.1526-4610.42.s2.7.x]

*Issue with no volume*

- 8 **Banit DM**, Kaufer H, Hartford JM. Intraoperative frozen

section analysis in revision total joint arthroplasty. *Clin Orthop Relat Res* 2002; **(401)**: 230-238 [PMID: 12151900 DOI: 10.1097/00003086-200208000-00026]

*No volume or issue*

- 9 Outreach: Bringing HIV-positive individuals into care. *HRS-A Careaction* 2002; 1-6 [PMID: 12154804]

### Books

*Personal author(s)*

- 10 **Sherlock S**, Dooley J. Diseases of the liver and biliary system. 9th ed. Oxford: Blackwell Sci Pub, 1993: 258-296

*Chapter in a book (list all authors)*

- 11 **Lam SK**. Academic investigator's perspectives of medical treatment for peptic ulcer. In: Swabb EA, Azabo S. Ulcer disease: investigation and basis for therapy. New York: Marcel Dekker, 1991: 431-450

*Author(s) and editor(s)*

- 12 **Breedlove GK**, Schorffheide AM. Adolescent pregnancy. 2nd ed. Wicczorek RR, editor. White Plains (NY): March of Dimes Education Services, 2001: 20-34

*Conference proceedings*

- 13 **Harnden P**, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ cell tumours Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer, 2002: 30-56

*Conference paper*

- 14 **Christensen S**, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer, 2002: 182-191

**Electronic journal** (list all authors)

- 15 Morse SS. Factors in the emergence of infectious diseases. Emerg Infect Dis serial online, 1995-01-03, cited 1996-06-05; 1(1): 24 screens. Available from: URL: <http://www.cdc.gov/ncidod/eid/index.htm>

**Patent** (list all authors)

- 16 **Pagedas AC**, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1

### Statistical data

Write as mean  $\pm$  SD or mean  $\pm$  SE.

### Statistical expression

Express *t* test as *t* (in italics), *F* test as *F* (in italics), chi square test as  $\chi^2$  (in Greek), related coefficient as *r* (in italics), degree of freedom as *ν* (in Greek), sample number as *n* (in italics), and probability as *P* (in italics).

### Units

Use SI units. For example: body mass, *m* (B) = 78 kg; blood pressure, *p* (B) = 16.2/12.3 kPa; incubation time, *t* (incubation) = 96 h, blood glucose concentration, *c* (glucose)  $6.4 \pm 2.1$  mmol/L; blood CEA mass concentration, *p* (CEA) = 8.6  $24.5 \mu\text{g/L}$ ; CO<sub>2</sub> volume fraction, 50 mL/L CO<sub>2</sub>, not 5% CO<sub>2</sub>; likewise for 40 g/L formaldehyde, not 10% formalin; and mass fraction, 8 ng/g, etc. Arabic numerals such as 23, 243, 641 should be read 23 243 641.

The format for how to accurately write common units and quantums can be found at: [http://www.wjgnet.com/2218-5836/g\\_info\\_20100724204625.htm](http://www.wjgnet.com/2218-5836/g_info_20100724204625.htm).

### Abbreviations

Standard abbreviations should be defined in the abstract and on first mention in the text. In general, terms should not be abbreviated unless they are used repeatedly and the abbreviation is helpful to the reader. Permissible abbreviations are listed in Units, Symbols and Abbreviations: A Guide for Biological and Medical Editors and Authors (Ed. Baron DN, 1988) published by The Royal Society of Medicine, London. Certain commonly used abbreviations, such as

DNA, RNA, HIV, LD50, PCR, HBV, ECG, WBC, RBC, CT, ESR, CSF, IgG, ELISA, PBS, ATP, EDTA, mAb, can be used directly without further explanation.

### Italics

Quantities: *t* time or temperature, *c* concentration, *A* area, *l* length, *m* mass, *V* volume.

Genotypes: *gyrA*, *arg* 1, *c myc*, *c fos*, etc.

Restriction enzymes: *EcoRI*, *HindI*, *BamHI*, *Kho* I, *Kpn* I, etc.

Biology: *H. pylori*, *E. coli*, etc.

### Examples for paper writing

**Editorial:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723140942.htm](http://www.wjnet.com/2218-5836/g_info_20100723140942.htm)

**Frontier:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723141035.htm](http://www.wjnet.com/2218-5836/g_info_20100723141035.htm)

**Topic highlight:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723141239.htm](http://www.wjnet.com/2218-5836/g_info_20100723141239.htm)

**Observation:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723141532.htm](http://www.wjnet.com/2218-5836/g_info_20100723141532.htm)

**Guidelines for basic research:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723142040.htm](http://www.wjnet.com/2218-5836/g_info_20100723142040.htm)

**Guidelines for clinical practice:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723142248.htm](http://www.wjnet.com/2218-5836/g_info_20100723142248.htm)

**Review:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723145519.htm](http://www.wjnet.com/2218-5836/g_info_20100723145519.htm)

**Original articles:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723145856.htm](http://www.wjnet.com/2218-5836/g_info_20100723145856.htm)

**Brief articles:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723150253.htm](http://www.wjnet.com/2218-5836/g_info_20100723150253.htm)

**Case report:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723150420.htm](http://www.wjnet.com/2218-5836/g_info_20100723150420.htm)

**Letters to the editor:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723150642.htm](http://www.wjnet.com/2218-5836/g_info_20100723150642.htm)

**Book reviews:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723150839.htm](http://www.wjnet.com/2218-5836/g_info_20100723150839.htm)

**Guidelines:** [http://www.wjnet.com/2218-5836/g\\_info\\_20100723150924.htm](http://www.wjnet.com/2218-5836/g_info_20100723150924.htm)

## SUBMISSION OF THE REVISED MANUSCRIPTS AFTER ACCEPTED

Please revise your article according to the revision policies of *WJO*. The revised version including manuscript and high-resolution image figures (if any) should be copied on a floppy or compact disk. The author should send the revised manuscript, along with printed high-resolution color or black and white photos, copyright transfer letter, and responses to the reviewers by courier (such as EMS/DHL).

### Editorial Office

### World Journal of Orthopedics

Editorial Department: Room 903, Building D,  
Ocean International Center,  
No. 62 Dongsihuan Zhonglu,  
Chaoyang District, Beijing 100025, China

E-mail: [wjo@wjnet.com](mailto:wjo@wjnet.com)

<http://www.wjnet.com>

Telephone: +86-10-8538-1892

Fax: +86-10-8538-1893

### Language evaluation

The language of a manuscript will be graded before it is sent for revision. (1) Grade A: priority publishing; (2) Grade B: minor language polishing; (3) Grade C: a great deal of language polishing needed; and (4) Grade D: rejected. Revised articles should reach Grade A or B.

### Copyright assignment form

Please download a Copyright assignment form from [http://www.wjnet.com/2218-5836/g\\_info\\_20100724204516.htm](http://www.wjnet.com/2218-5836/g_info_20100724204516.htm).

### Responses to reviewers

Please revise your article according to the comments/suggestions provided by the reviewers. The format for responses to the reviewers' comments can be found at: [http://www.wjnet.com/2218-5836/g\\_info\\_20100724204306.htm](http://www.wjnet.com/2218-5836/g_info_20100724204306.htm).

### Proof of financial support

For paper supported by a foundation, authors should provide a copy of the document and serial number of the foundation.

### Links to documents related to the manuscript

*WJO* will be initiating a platform to promote dynamic interactions between the editors, peer reviewers, readers and authors. After a manuscript is published online, links to the PDF version of the submitted manuscript, the peer-reviewers' report and the revised manuscript will be put on-line. Readers can make comments on the peer reviewer's report, authors' responses to peer reviewers, and the revised manuscript. We hope that authors will benefit from this feedback and be able to revise the manuscript accordingly in a timely manner.

### Science news releases

Authors of accepted manuscripts are suggested to write a science news item to promote their articles. The news will be released rapidly at EurekaAlert/AAAS (<http://www.eurekalert.org>). The title for news items should be less than 90 characters; the summary should be less than 75 words; and main body less than 500 words. Science news items should be lawful, ethical, and strictly based on your original content with an attractive title and interesting pictures.

### Publication fee

*WJO* is an international, peer-reviewed, Open-Access, online journal. Articles published by this journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. Authors of accepted articles must pay a publication fee. The related standards are as follows. Publication fee: 1300 USD per article. Editorial, topic highlights, original articles, book reviews and letters to the editor are published free of charge.